.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CB05_Pasireotide.Pasireotide

Information

Pasireotide is a synthetic somatostatin analog, used primarily in the treatment of Cushing’s disease and acromegaly when surgery is not effective or feasible. It acts by binding to multiple somatostatin receptor subtypes to inhibit ACTH secretion. It is an approved drug and used today, mainly for endocrine disorders.

Pharmacokinetics

Pharmacokinetic parameters reported for adult healthy volunteers (both sexes) after subcutaneous administration of pasireotide in clinical studies.

References

1. Nedelman, J, et al., & Zhou, J (2018). Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients. Clinical pharmacokinetics 57(7) 855–866. DOI:10.1007/s40262-017-0600-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/29032486

2. Chen, X, et al., & Hu, P (2014). Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clinical therapeutics 36(8) 1196–1210. DOI:10.1016/j.clinthera.2014.06.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25012727

3. Huang, CJ, et al., & Shih, KC (2023). Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study. European journal of drug metabolism and pharmacokinetics 48(6) 665–674. DOI:10.1007/s13318-023-00854-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37751056

Revisions

• 06/2025 initial generated model